Loading...
ESMO Asia congresses2023-07-14T14:36:54+01:00

ESMO Asia 2015 – Singapore

Lecture Board: Maximilan Hochmair MD, Robert Pirker MD, Martin Reck MD, Suresh Senan, MD, Frances Shepherd MD
Medical Writer: Judith Moser, MD

DOWNLOADS

All downloads from ESMO Asia 2015

ESMO Asia 2015 English

Full report (english)

ESMO Asia 2015 Mandarin

Full report (mandarin)

Immunotherapy represents an exciting new option, particularly in patients with squamous cell cancer, and in prior or current smokers. In the CheckMate 017 trial, the PD-1 inhibitor nivolumab provided clinically meaningful and statistically significant overall survival benefit independent of PD-L1 expression in a population of previously treated patients with advanced squamous-cell lung cancer.

Frances A. Shepherd
Go to Top